Douglas J. Manion

Insider Reports History

Location
Wayne, PA
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Douglas J. Manion:

Form 4 holding Pres and CEO, Director

Aclaris Therapeutics, Inc.

Security class
Restricted Stock Units
Shares / value
81,000
Estimated value
$85,050
Report date
01 Jan 2024
Price
$1.05
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Pres and CEO, Director

Aclaris Therapeutics, Inc.

Security class
Common Stock
Shares / value
41,813
Estimated value
$43,904
Report date
01 Jan 2024
Price
$1.05
Ownership
Direct
Form 4 holding EVP Research & Development

ARENA PHARMACEUTICALS INC

Security class
Common Stock
Shares / value
0
Estimated value
Report date
11 Mar 2022
Price
$98.51
Ownership
Direct
Form 4 holding EVP Research & Development

ARENA PHARMACEUTICALS INC

Security class
Employee Performance Restricted Stock Unit
Shares / value
0
Estimated value
Report date
11 Mar 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding EVP Research & Development

ARENA PHARMACEUTICALS INC

Security class
Employee Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
11 Mar 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Douglas J. Manion

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .